An invivo study to evaluate the role of curcumin in oral pre-malignant lesions and gingivo-buccal cancers

DBT0 个研究点目标入组 90 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•? Age > 18 years
•? Histologically confirmed resectable oral cavity cancer (T3, T4a) with a co-existent premalignant condition i.e. leukoplakia or submucous fibrosis.
•? Gives informed consent
•? Previously untreated
•? WHO performance status of < 1
•? Laboratory values (performed within 14 days prior to administration of Curcumin)
•? WBC count > 3.0 x 109 /L
•? Platelet count ≥ 150 x 109 /L
•? Hemoglobin ≥ 10 gm/dl (100 gm/l)
•? Serum creatinine less than 1.5 times the upper normal limit
•? Total bilirubin less than 1.5 times the upper normal limit
•? SGOT or SGPT ≤ 5.0 times upper limit of normal
•? Negative Pregnancy test (female patients of childbearing potential only)

•? The patient is < 18 years or >75 years of age
•? The patient has had chemotherapy, immunotherapy, hormonal therapy, or radiation therapy within 4 weeks of the baseline visit
•? The patient will need concurrent chemotherapy, radiotherapy, hormonal (other than HRT for menopause), or immunotherapy during the time of study
•? The patient has history of any form of cancer within the past three years (excluding non-melanoma skin cancer and in situ cervical cancer)
•? The patient has received any investigational medication within 30 days of starting the curcumin therapy
•? The patient is participating in any other study

发起方